Literature DB >> 7605420

Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children.

K T Olkkola1, K Hamunen, T Seppälä, E L Maunuksela.   

Abstract

1. Oxycodone hydrochloride (0.1 mg kg-1) was given by intravenous bolus to 18 children after ophthalmic surgery. Plasma was sampled for up to 8 h. Blood pressure, heart rate, peripheral arteriolar oxygen saturation, end-tidal carbon dioxide and halothane concentrations and ventilatory rate were also recorded. 2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1. Maximum mean end-tidal carbon dioxide concentration and minimum mean ventilatory rate occurred 8 min after administration of oxycodone but the minimum mean peripheral arteriolar oxygen saturation occurred at 4 min. 3. Oxycodone (0.1 mg kg-1) appears to cause greater ventilatory depression than comparable analgesic doses of other opioids.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7605420      PMCID: PMC1364840          DOI: 10.1111/j.1365-2125.1994.tb04324.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays.

Authors:  E Kalso; A Vainio; M J Mattila; P H Rosenberg; T Seppälä
Journal:  Pharmacol Toxicol       Date:  1990-10

3.  The pharmacokinetics of oxycodone after intravenous injection in adults.

Authors:  R Pöyhiä; K T Olkkola; T Seppälä; E Kalso
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 4.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

5.  Morphine and oxycodone hydrochloride in the management of cancer pain.

Authors:  E Kalso; A Vainio
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

6.  Pharmacokinetics of pethidine during anaesthesia and patient-controlled analgesic therapy.

Authors:  P Hartvig; A Tamsen; C Fagerlund; B Dahlström
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1982

7.  The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow.

Authors:  C S Reilly; A J Wood; R P Koshakji; M Wood
Journal:  Anesthesiology       Date:  1985-07       Impact factor: 7.892

Review 8.  Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

9.  Oesophageal compliance in naturally occurring canine megaoesophagus.

Authors:  C T Holland; P M Satchell; B R Farrow
Journal:  Aust Vet J       Date:  1993-11       Impact factor: 1.281

10.  Measurement of pain in children with self-reporting and behavioral assessment.

Authors:  E L Maunuksela; K T Olkkola; R Korpela
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

View more
  14 in total

Review 1.  Strong opioids in pediatric palliative medicine.

Authors:  Richard D W Hain; Angela Miser; Mary Devins; W Hamish B Wallace
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Merja Lasalmi; Sanna Lehtola; Veli-Pekka Ranta; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children.

Authors:  E Kalso
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

4.  Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.

Authors:  Antti Liukas; Kristiina Kuusniemi; Riku Aantaa; Petri Virolainen; Mikko Neuvonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

Review 5.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

6.  Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.

Authors:  Merja Kokki; Marja Heikkinen; Pyry Välitalo; Heidi Hautajärvi; Juho Hokkanen; Hanna Pitkänen; Ulla Sankilampi; Veli-Pekka Ranta; Hannu Kokki
Journal:  Br J Clin Pharmacol       Date:  2016-12-05       Impact factor: 4.335

7.  Maturation of Oxycodone Pharmacokinetics in Neonates and Infants: a Population Pharmacokinetic Model of Three Clinical Trials.

Authors:  Pyry Välitalo; Merja Kokki; Veli-Pekka Ranta; Klaus T Olkkola; Andrew C Hooker; Hannu Kokki
Journal:  Pharm Res       Date:  2017-02-15       Impact factor: 4.200

Review 8.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Matti Reinikainen; Pekka Suhonen; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.

Authors:  Liang Zheng; Miao Xu; Shi-Wei Tang; Hao-Xin Song; Xue-Hua Jiang; Ling Wang
Journal:  Pharm Res       Date:  2019-10-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.